Previous studies in established type 2 diabetes patients have demonstrated underutilization of GLP‐1 receptor agonists [10] and SGLT‐2 inhibitors in patients with established CVD and/or CKD [11] that is particularly pronounced in underserved populations [12, 13, 14]. This evidence concerns the gene SLC5A2 and chronic kidney disease.